Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
Get Alerts TMO Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $5 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251106864636/en/
Media Contact Information:
Sandy Pound
781-622-1223
[email protected]
Investor Contact Information:
Rafael Tejada
781-622-1356
[email protected]
Source: Thermo Fisher Scientific Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenstone Biosciences Awarded Breakthrough T1D Grant to Advance Islet Cell Platform
- Goodwin University Partners with 3SquaresVT to Offer Exclusive No-Cost Training Programs
- Kia and its Dealers Expand Community Giving Nationwide
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share